BeiGene (NASDAQ:BGNE) Posts Quarterly Earnings Results

BeiGene (NASDAQ:BGNE - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04), Briefing.com reports. BeiGene had a negative return on equity of 25.15% and a negative net margin of 25.94%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. During the same period in the prior year, the firm earned $2.01 earnings per share. The business's revenue for the quarter was up 28.2% compared to the same quarter last year.

BeiGene Stock Performance

Shares of NASDAQ:BGNE traded up $1.81 during midday trading on Wednesday, hitting $195.45. The company had a trading volume of 281,526 shares, compared to its average volume of 265,109. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.98 and a quick ratio of 1.75. The company has a market cap of $19.04 billion, a price-to-earnings ratio of -23.72 and a beta of 0.63. BeiGene has a 12-month low of $126.97 and a 12-month high of $248.16. The company has a fifty day moving average of $212.91 and a two-hundred day moving average of $181.72.

Insider Transactions at BeiGene

In other news, CEO John Oyler sold 6,175 shares of the company's stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO John Oyler sold 6,175 shares of the company's stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total value of $1,433,958.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Xiaobin Wu sold 5,556 shares of the company's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total transaction of $1,053,695.40. The disclosure for this sale can be found here. Insiders sold 23,070 shares of company stock worth $4,901,050 in the last three months. Corporate insiders own 7.43% of the company's stock.

Wall Street Analyst Weigh In

BGNE has been the subject of a number of recent analyst reports. JMP Securities initiated coverage on shares of BeiGene in a report on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price objective for the company. Citigroup boosted their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. TD Cowen boosted their target price on shares of BeiGene from $254.00 to $260.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research note on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $247.07.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.